None listed
Conditions
Brief summary
This study aims to investigate whether zoledronic acid is effective in slowing bone erosion/lysis in patients with psoriatic arthritis. ÿ¢ÿ¿ÿ¿ comparison with placebo. Bone damage to be assessed using MRI scans and XRays. Secondary outcomes assessed include BMD, ositeoclast function and bone turnover markers.
Interventions
Zoledronic acid for treatment of erosive psoriatic arthritis: double blind randomised placebo controlled study. One year duration ( 4 IV injections at 3 month intervals).
Sponsors
University of Auckland
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Psoriatic arthritis (according to Vasey and Espinoza criteria)Erosive PsA (bone lysis/ erosion peripheral joints on XR confirmed by a radiologist). Disease duration > 6 months. Suitable for MR scan* Adequate contraception if applicable DMARD, on a stable dose for 8 weeks prior to randomization Oral Prednisone no > 10mg daily at least 3 swollen and 3 tender joints.
Exclusion criteria
Severe kidney, liver or heart disease Deranged calcium or Vit D levelsUveitis, Iritis, or chronic Conjunctivitis (or history of these conditions)Diabetic eye or kidney disease Uncontrolled diabetes, Hb1AC > 10 % Cancer (metastatic cancer or cancer diagnosed < 2 years ago) Is pregnant or planning pregnancy Severe dental problems or current dental infection, recent or impending dental surgery within three months of enrolmentOrthopaedic surgery within 3 months of enrolment Fractures (within the last 3 months) Use of Bisphosphonate therapy Participant in any biologics trial within 6 months.
Outcome results
None listed